Structural Study Supports Development of Proteasome-Inhibitor Antimalarials

A recent study by researchers at Weill Cornell Medicine and Van Andel Institute has shed light on the structural secrets behind a potent antimalarial drug candidate, TDI-8304, providing a pathway for the development of drug-resistant malaria therapies. TDI-8304 belongs to a novel class of experimental therapeutics targeting the proteasome, a vital complex in Plasmodium falciparum (P. falciparum) cells, the major cause of malaria deaths.

Published in Nature Communications, the study utilized cryo-electron microscopy (cryo-EM) to demonstrate how TDI-8304 binds to its proteasome target at high resolution. This advanced imaging also unveiled the consequences when P. falciparum mutates to reduce sensitivity to TDI-8304, offering crucial insights for the development of new antimalarials less prone to resistance.

Dr. Gang Lin, study co-senior author, highlighted that the research provides insights for the development of proteasome-inhibitor antimalarials less susceptible to resistance. Intriguingly, the mutation that reduces sensitivity to TDI-8304 increases susceptibility to compounds targeting a different part of the parasite proteasome, revealing a phenomenon termed "collateral sensitivity."

The structural insights from cryo-EM studies illuminated the strengths and weaknesses of TDI-8304. It was revealed that the drug forms extensive connections with its target, and the mutation weakens these connections, providing a blueprint for understanding resistance mechanisms.

The researchers envision leveraging these findings to develop therapeutics that strategically target multiple proteasome sites, aiming to delay the emergence of resistance.